Form 4: Allogene EVP Sells Shares for Tax, Gains New Equity Awards

Allogene Therapeutics' EVP of R&D, Zachary Roberts, sold 35,700 shares to cover tax obligations while simultaneously receiving new stock options and restricted stock units.

Summary

• Zachary Roberts, EVP of R&D at Allogene Therapeutics, Inc., reported transactions on February 2, 2026.
• Sold 35,700 shares of common stock at a weighted average price of $1.77 per share (ranging from $1.71 to $1.87) to cover tax withholding obligations related to the vesting of restricted stock units.
• The sale was mandated by the Issuer's equity incentive plan and was not a discretionary trade by the reporting person.
• Acquired a stock option for 718,763 shares of common stock with an exercise price of $1.87, which will vest 25% on February 2, 2027, and the remaining shares in 36 equal monthly installments thereafter.
• Received an award of 203,307 Restricted Stock Units (RSUs), which will vest in 4 successive equal annual installments over a four-year period measured from February 2, 2026, subject to continued service.
• Following these reported transactions, Roberts beneficially owns 581,166 shares of common stock, 718,763 stock options, and 203,307 RSUs.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as the executive received substantial new equity awards, indicating continued commitment and incentive, while the share sale was non-discretionary for tax purposes.

Positives

• The grant of 718,763 stock options and 203,307 Restricted Stock Units indicates continued incentive and alignment of management with shareholder interests.
• The 'sell to cover' transaction is explicitly stated as non-discretionary and mandated for tax withholding, suggesting no negative sentiment from the executive regarding the company's future prospects.

Negatives

• The sale of 35,700 shares, even if for tax purposes, reduces the executive's direct shareholding in the company.

Risks

• Future stock price volatility could impact the ultimate value realized from the executive's equity awards.
• The vesting of both stock options and Restricted Stock Units is subject to continued service, posing a retention risk if the executive departs before full vesting.

Future Outlook

The grant of new equity awards to a key executive suggests a long-term commitment to the company's future performance and aligns the executive's incentives with potential future stock price appreciation, contingent on continued service.

Management Comments

• The sale of 35,700 shares represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units, mandated by the Issuer's equity incentive plan, and does not represent a discretionary trade.

Industry Context

StockSavvy.ai notes that equity compensation, including stock options and restricted stock units, is a standard practice in the biotechnology and pharmaceutical industry to attract, retain, and incentivize key executives, particularly in R&D roles where long-term development cycles are common. This aligns the executive's financial interests with the company's long-term success and shareholder value creation.

Comparison to Industry Standards

• The structure of equity awards, with multi-year vesting schedules for both stock options (4 years) and RSUs (4 years), is consistent with typical executive compensation packages in the biotech sector, similar to practices observed at companies like Gilead Sciences or Amgen, which use long-term incentives to retain talent.
• The 'sell to cover' mechanism for tax withholding is a common and widely accepted practice for managing tax liabilities arising from equity vesting, seen across various industries and companies of similar market capitalization.

Stakeholder Impact

• Shareholders: The grant of new equity awards aligns the executive's long-term interests with shareholder value creation, potentially incentivizing performance in their R&D role.
• Employees: The compensation structure reflects standard practices for executive incentives within the company and the broader industry, which can influence overall employee compensation philosophy and retention strategies.

Next Steps

• Continued service through vesting dates for both stock options and Restricted Stock Units will be required for the executive to realize the full value of these awards.
• Future vesting events will trigger additional tax obligations and potentially more 'sell to cover' transactions.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation activities, including the grant of new equity awards and a non-discretionary 'sell to cover' transaction for tax purposes. It does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. The executive's continued receipt of significant equity compensation suggests ongoing commitment, which is a neutral to slightly positive signal, but insufficient to alter a broader investment thesis.

Keywords

Allogene Therapeutics, ALLO, Zachary Roberts, EVP R&D, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Compensation, Sell to Cover, Executive Compensation